Plain-English translation of NCT07700940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a medication called empagliflozin can help protect and improve kidney function in people with lupus nephritis—a condition where lupus damages the kidneys. The medication has already been shown to slow kidney disease in other patient groups, but it has never been studied in people with lupus nephritis. This study will compare this treatment to a placebo (a dummy pill) to see if it can reduce protein in the urine and preserve kidney function.
Lupus nephritis is a serious complication that affects many people with lupus and can lead to kidney failure. While this medication has helped protect kidneys in patients with other types of kidney disease, it has not yet been tested in the lupus population. This trial aims to fill that gap and see if this treatment could offer a new way to help protect lupus patients' kidneys.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the medication or a placebo once daily. You will need to visit the clinic regularly so doctors can monitor your kidney function and protein levels through blood and urine tests. The study is designed to track your kidney health over time to see whether the medication helps slow kidney damage compared to placebo.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Egypt